Checkpoint Blockade + Chemotherapy: the Right Combination for AML?

Blood Cancer Discov. 2021 Nov;2(6):551-554. doi: 10.1158/2643-3230.BCD-21-0130. Epub 2021 Sep 10.

Abstract

An emerging strategy to enhance the efficacy of immune checkpoint blockade in relapsed/refractory cancers is increasing immunogenic cell death via combination with cytotoxic therapies. Understanding the effects of cytotoxic and immunotherapeutic agents on immune cell populations will enable improved mechanism-based design of combination therapies to maximum efficacy and minimum toxicity.See related article by Zeidner et al., p. 616.

Publication types

  • Comment